bismuth
use
medicin
two
centuri
treatment
variou
diseas
particular
gastrointestin
disord
owe
antimicrobi
activ
recent
structur
character
bismuth
drug
provid
insight
assembl
pharmacokinet
pathway
drug
mine
potenti
protein
target
insid
pathogen
via
metallomicmetalloproteom
approach
character
interact
bismuth
drug
target
laid
foundat
understand
mechan
action
bismuth
drug
studi
would
benefici
ration
design
new
potenti
drug
bioinorgan
chemistri
bismuth
li
sun
figur
continu
structur
structur
model
bismuth
citrat
bismuth
subsubsalicyl
bss
dimer
bismuth
citrat
build
block
ballstick
model
polyhedr
b
polymer
framework
bismuth
citrat
link
three
type
bismuth
citrat
build
block
repres
adjac
green
blue
purpl
polyhedr
respect
c
twodimension
polymer
structur
polymer
framework
pyridin
ring
channel
repres
spacefil
mode
structur
model
rantidin
bismuth
citrat
ranitidin
insert
channel
e
core
structur
bismuth
subsubsalicyl
bi
hsal
ch
co
show
shroud
bi
core
salicyl
ligand
stick
structur
f
structur
bi
core
show
octahedr
arrang
bismuth
atom
ark
brown
ball
seven
octahedr
face
cap
oxygen
atom
red
ball
bismuth
compound
use
medicin
year
treatment
variou
diseas
includ
syphili
hypertens
infect
skin
condit
gastrointestin
disord
discoveri
helicobact
pylori
h
pylori
gramneg
bacterium
gastric
mucosa
respons
gastric
duoden
ulcer
promot
research
medic
applic
bismuth
current
three
bismuth
drug
bismuth
subsalicyl
peptobismol
colloid
bismuth
subcitr
denol
ranitidin
bismuth
citrat
tritec
pylorid
use
worldwid
combin
antibiot
erad
h
pylori
infect
addit
mani
new
bismuth
compound
differ
structur
activ
well
bismuth
nanotub
synthes
past
year
enorm
effort
made
toward
understand
structur
well
mechan
action
bismuth
drug
recent
advanc
biophys
molecular
biolog
provid
invalu
tool
necessari
studi
bioinorgan
chemistri
bismuth
exampl
timeresolv
induct
coupl
plasma
mass
spectrometri
enabl
bismuth
antiulc
drug
track
singl
helicobact
pylori
cell
ca
bi
atomscel
uptak
bismuth
helicobact
pylori
retard
ferric
ion
fe
suggest
bismuth
drug
may
util
certain
irontransport
pathway
pathogen
number
protein
target
bismuth
drug
particular
h
pylori
identifi
metallom
metalloproteom
approach
sever
comprehens
review
summar
chemistri
biolog
chemistri
bismuth
well
medic
applic
avail
recent
focu
recent
advanc
structur
protein
target
bismuth
drug
well
design
potenti
activ
new
bismuth
complex
spite
extens
clinic
usag
bismuth
drug
structur
drug
unveil
past
two
decad
variou
bismuth
citrat
complex
differ
bismuth
citrat
ratio
crystal
differ
ph
valu
among
structur
obtain
acid
condit
ph
probabl
repres
real
situat
stomach
colloid
bismuth
subcitr
cb
like
assembl
sheet
threedimension
polym
use
bismuth
citrat
dinuclear
unit
bi
cit
bi
build
block
form
protect
coat
ulcer
crater
crystal
structur
four
bismuth
citrat
complex
obtain
acid
ph
valu
presenc
either
ethylenediamin
pyridin
reveal
bismuth
citrat
dimer
unit
bi
cit
bi
figur
serv
basic
build
block
lead
polymer
structur
regular
mesh
intern
caviti
proton
ethylenediamin
despit
unobserv
structur
figur
pyridin
moieti
figur
embed
probabl
diffus
electrostat
interact
polymer
framework
achiev
charg
balanc
sinc
citrat
anion
found
structur
deproton
lead
citrat
tetrannion
c
h
composit
bismuth
citrat
complex
framework
depend
size
level
proton
insert
cation
ph
valu
well
time
crystal
structur
model
ranitidin
bismuth
citrat
rbc
construct
base
framework
crystal
structur
complex
ranitidin
molecul
readili
embed
caviti
perpendicular
bc
plane
hbond
form
ranitidin
bound
citrat
ligand
figur
addit
sulfur
atom
ranitidin
form
hbond
water
molecul
coordin
bismuth
base
xray
crystal
structur
well
esim
bismuth
citrat
complex
like
bismuth
citratebas
drug
degrad
gastric
acid
condit
ph
polym
framework
polymer
sheet
final
basic
dimer
unit
bi
cit
bi
absorb
transport
membran
receptor
bismuth
subsalicyl
peptobismol
bss
one
commonli
use
bismuth
drug
structur
character
bismuth
carboxyl
challeng
owe
difficulti
control
hydrolysi
complex
format
coordin
oligomerspolym
co
figur
may
provid
insight
natur
bss
basi
studi
mode
action
drug
crystal
bi
hsal
co
co
initi
predomin
rel
small
amount
larg
cluster
bismuth
atom
appear
least
solubl
thermodynam
stabl
form
extend
crystal
growth
time
structur
contain
basic
build
block
bi
polyhedron
found
bismuth
oxo
cluster
six
octahedr
bi
atom
eight
atom
locat
triangular
face
core
two
structur
bi
cluster
compris
central
bi
octahedron
seven
eight
trigon
face
cap
atom
shown
figur
structur
bismuth
also
coordin
solvent
molecul
aceton
replac
solvent
molecul
dmf
dimethyflormamid
crystal
solvent
interestingli
core
bi
hsal
first
structur
bss
without
organ
auxiliari
obtain
xray
diffract
data
bismuth
disalicyl
powder
gave
rise
twodimension
polym
held
bio
linkag
hydrogen
bond
one
bismuth
atom
one
salicyl
monoanion
one
salicyl
dianion
unit
monoanion
salicyl
coordin
singl
bi
ion
carboxyl
group
dianion
salicyl
employ
phenoxid
oxygen
atom
bridg
ligand
form
fourmemb
bi
ring
addit
oxygen
atom
water
molecul
bond
bismuth
structur
bss
resembl
bismuth
complex
substitut
benzoic
acid
past
decad
signific
work
devot
develop
new
bismuth
drug
variou
new
bismuthcontain
complex
synthes
show
promis
vitro
activ
h
pylori
importantli
bismuthcontain
complex
demonstr
exhibit
new
vitro
activ
includ
antifung
antivir
even
anticanc
activ
bismuth
drug
bss
cb
rbc
effect
treat
erad
helicobact
pylori
togeth
antibiot
howev
nonsteroid
antiinflammatori
drug
nsaid
may
also
caus
gastrointestin
damag
bismuth
deriv
nsaid
exhibit
good
vitro
activ
three
strain
h
pylori
minimum
inhibitori
concentr
mic
mgml
better
commerci
use
bss
mgml
laboratori
prepar
bismuth
salicyl
mgml
cb
mgml
therefor
compound
may
great
potenti
treatment
h
pylori
show
signific
activ
h
pylori
mic
mgml
cyclic
organobismuth
compound
bear
nitrogen
sulfur
atom
addit
ring
member
also
exhibit
variou
antibacteri
activ
includ
gramposit
gramneg
bacteria
although
bismuthcontain
complex
show
vitro
activ
h
pylori
pathogen
appear
lack
vivo
data
work
warrant
promot
medic
applic
complex
besid
antibacteri
activ
bismuth
complex
substitut
benzoic
acid
also
exhibit
signific
antileishmani
activ
promastigot
l
major
heterocycl
organobismuth
compound
cl
h
tbu
cf
f
n
exert
antifung
activ
saccharomyc
cerevisia
activ
depend
lipophil
compound
higher
lipophil
lower
antifung
activ
organobismuth
compound
also
found
exhibit
antitumor
potenti
bismuth
xanthat
complex
bi
cor
r
et
ipr
cyclohexyl
shown
exert
cytotox
activ
lung
adenocarcinoma
similar
ic
valu
cisplatin
indic
compound
potenc
compar
cisplatin
moreov
bismuth
complex
also
exert
cytotox
activ
cisplatininsensit
mammari
carcinoma
bismuth
dithiocarbam
complex
gener
formula
bi
cnr
also
demonstr
exhibit
potent
vitro
cytotox
panel
seven
human
cancer
cell
line
heterocycl
organobismuth
compound
potent
cytotox
activ
variou
cancer
cell
line
ic
rang
mm
particular
sensit
toward
leukem
cell
line
bismuth
compound
bichlorodibenzo
c
f
thiabismocin
may
induc
apoptosi
cell
activ
caspas
product
ro
perturb
mitochondria
may
also
target
tubulin
induc
arrest
hela
cell
probabl
interact
colchicinesbind
site
thiolat
sh
group
type
organobismuth
compound
may
util
antimitot
agent
treatment
refractori
acut
promyelocyt
leukemia
similar
arsen
trioxid
antivir
activ
bismuth
complex
explor
sever
acut
respiratori
syndrom
coronaviru
sarscov
envelop
singlestrand
rna
positivestrand
viru
kill
hundr
peopl
worldwid
broken
seri
bismuth
complex
includ
bismuth
nitrilotriacet
bi
nta
bismuth
tricystein
bi
cy
rbc
bismuth
ethylenediaminetetraacet
bi
edta
well
bismuth
complex
variou
n
ocontain
chelat
ligand
includ
bismuth
porphyrin
complex
examin
sarscov
helicas
postul
potenti
target
antisar
therapi
major
bismuth
complex
test
exhibit
activ
sarscov
helicas
atpas
duplexunwind
activ
highest
activ
found
rbc
bismuth
porphyrin
complex
ic
valu
less
mm
bi
edta
two
bismuth
complex
n
ocontain
chelat
ligand
show
almost
activ
indic
differ
inhibit
activ
complex
correl
differ
coordin
environ
higher
affin
bismuth
toward
chelat
ligand
lower
activ
treatment
sarscov
infect
cell
bismuthcontain
complex
rbc
bi
htf
htf
human
transferrin
confirm
inhibitori
role
bismuth
later
stage
replic
cycl
studi
repres
first
attempt
use
bismuth
antiviru
agent
although
work
requir
elucid
activ
mechan
action
bismuth
drug
complic
fulli
understood
gener
believ
bismuth
drug
taken
gastric
mucu
form
protect
coat
probabl
biocl
bismuth
citrat
complex
ulcer
crater
may
inhibit
helicobact
pylori
adher
also
bind
strongli
connect
tissu
protein
mucu
glycoprotein
enzym
accumul
studi
demonstr
protein
peptid
like
potenti
target
drug
bismuth
drug
shown
interact
rang
protein
human
serum
transferrin
lactoferrin
serum
albumin
metallothionein
bind
bismuth
lactoferrin
may
depriv
iron
acquisit
h
pylori
sinc
bacteria
util
hostspecif
lactoferrin
iron
acquisit
level
bismuth
uptak
h
pylori
singl
cell
also
found
revers
correl
level
iron
bismuth
drug
also
demonstr
inhibit
sever
enzym
h
pylori
inhibit
activ
yeast
alcohol
dehydrogenas
interf
zinc
site
alter
enzym
nativ
structur
bismuth
uptaken
pathogen
h
pylori
may
target
sever
protein
insid
pathogen
inhibit
synthesi
essenti
enzym
ureas
hydrogenas
nickelbind
protein
critic
bacteri
surviv
recent
metallom
metalloproteom
approach
use
investig
role
metal
biolog
system
search
put
bind
protein
target
bismuth
drug
insid
bacterium
recent
advanc
area
updat
sinc
inform
summar
elsewher
ureas
account
total
cellular
protein
essenti
nickelcontain
enzym
h
pylori
colon
virul
catalyz
hydrolysi
urea
yield
carbam
ammonia
thu
neutral
immedi
environ
bacterium
aid
surviv
acid
condit
gastric
lumen
mucosa
bismuth
complex
rbc
well
triarylbismuthan
inhibit
ureas
activ
inhibit
jack
bean
ureas
triarylbismuthan
compound
good
agreement
observ
antibacteri
activ
compound
h
pylori
bi
edta
bi
cy
competit
inhibitor
jack
bean
ureas
rbc
noncompetit
inhibitor
kinet
analysi
demonstr
bi
edta
competit
inhibitor
timedepend
inactiv
recombin
klebsiella
areogen
ureas
inhibit
probabl
due
bind
bismuth
cystein
residu
enzym
klebsiella
areogen
probabl
jack
bean
ureas
entranc
activ
site
surviv
h
pylori
requir
constant
suppli
ni
ion
synthesi
activ
ni
enzym
like
bacteria
h
pylori
abl
strike
delic
balanc
import
ni
ion
effici
intracellular
storag
deliveri
ni
depend
metalloenzym
requir
h
pylori
abl
synthes
small
histidinerich
cytoplasm
protein
hpn
histidin
amino
acid
histidinerich
glutaminerich
protein
hpnl
histidin
glutamin
amino
acid
may
play
role
storag
nickel
ion
reservoir
donat
nickel
protein
detoxif
via
sequestr
excess
nickel
ion
depend
exogen
nickel
level
vitro
vivo
experi
suggest
hpn
hpnl
sequest
nickel
ion
neutral
ph
donat
probabl
ureas
activ
acid
condit
h
pylori
lack
hpnhpnl
gene
cultur
vitro
suscept
ni
bi
wildtyp
strain
essenti
metal
ion
ni
zn
cu
therapeut
metal
ion
exampl
bi
bind
hpn
vitro
indic
hpn
may
serv
potenti
target
bismuth
therapi
hpn
bind
ca
ae
ni
ae
bi
per
monom
probabl
via
multipl
imidazol
group
four
cy
residu
dissoci
constant
k
mm
respect
hpnlike
hpnl
bind
ca
ae
ni
per
monom
k
ae
mm
two
histidin
residu
identifi
play
critic
role
bind
ni
whether
hpnl
interact
bismuth
drug
known
may
warrant
studi
recent
fluoresc
reson
energi
transfer
fret
approach
allow
studi
metal
bind
properti
hpn
protein
sequenc
insert
fret
partner
cfp
yfp
vitro
vivo
found
hpnfret
express
model
system
exampl
e
coli
fret
chang
observ
addit
bismuth
subsalicyl
pepto
bismol
ni
zn
clearli
indic
hpn
potenti
target
bismuth
vivo
bind
bismuth
protein
may
therefor
interfer
normal
function
systemat
identif
potenti
target
metallodrug
achiev
nowaday
metallomicmetalloproteom
approach
shown
figur
immobilizedmet
affin
chromatographi
imac
combin
two
dimension
electrophoresi
malditof
mass
spectrometri
particularli
use
tool
elucid
metabol
intracellular
metal
ion
identifi
molecular
target
bind
protein
associ
diseas
etiolog
patholog
metallodrug
approach
use
first
time
search
potenti
protein
target
bismuth
drug
h
pylori
genomewid
scale
compar
proteom
analysi
h
pylori
cell
treatment
cb
perform
eight
protein
found
significantli
upregul
downregul
figur
protein
mainli
involv
either
cellular
process
hspa
hspb
put
alkyl
hydroperoxid
reductas
tsaa
neutrophilactiv
protein
napa
oxid
stress
resist
thioredoxin
hemoglobin
upregul
express
thioredoxin
low
redox
potenti
reduct
may
reflect
respons
h
pylori
high
level
oxid
stress
use
immobilizedbismuth
affin
chromatographi
biimac
seven
bismuthbind
protein
subsequ
identifi
h
pylori
cell
extract
figur
interestingli
intracellular
level
four
protein
exampl
hspa
hspb
napa
tsaa
decreas
upon
addit
cb
figur
suggest
protein
directli
bind
bismuth
bismuthbind
protein
identifi
includ
fumaras
ureas
subunit
ureb
translat
factor
eftu
furthermor
found
bismuth
led
around
decreas
cellular
proteas
activ
elev
level
lipid
hydroperoxid
hemin
whole
cell
extract
bismuthtr
h
pylori
cell
untreat
cell
valid
potenti
target
bismuth
drug
identifi
metalloproteom
approach
subsequ
studi
carri
exampl
fumaras
enzym
catalyz
revers
hydrat
fumar
malic
acid
bind
one
bi
per
monom
lead
appar
noncompetit
inhibit
enzym
hspa
member
groe
chaperonin
famili
small
protein
uniqu
histidin
cysteinerich
domain
c
terminu
sequenc
shown
figur
apart
normal
function
groe
exampl
aid
protein
fold
conjunct
groel
also
play
role
nickel
regul
facilit
nickel
acquisit
donat
nickel
appropri
protein
enzym
detoxif
excess
nickel
recombin
hspa
h
pylori
found
bind
two
bi
ion
two
ni
per
monom
protein
figur
ctermin
cysci
motif
histidin
residu
probabl
involv
bind
similar
hpn
potenti
role
hisrich
cysrich
terminu
vivo
examin
comparison
growth
e
coli
cell
express
wild
type
ctermin
delet
mutant
minim
medium
supplement
metal
ion
concentrationdepend
manor
e
coli
cell
express
ctermin
delet
mutant
suscept
increas
concentr
nickel
ion
contrast
bi
retard
growth
wild
typecontain
cell
surprisingli
apart
ctermin
metal
bind
domain
three
residu
found
critic
zn
bind
vivo
transit
metal
ion
ni
cu
fe
mn
residu
locat
ntermin
apic
domain
probabl
origin
neg
select
figur
make
oxidationsensit
zinc
bind
site
sinc
zn
hpgroesdmbd
restor
activ
enzym
alkalin
phosphatas
ap
equilibrium
dialysi
studi
show
bismuth
bind
ctermin
delet
hpgroe
hpgroesdmbd
similar
pattern
zn
affin
higher
bismuth
bind
ctermin
metal
bind
domain
competit
experi
bi
zn
react
hpgroesdmbd
indic
bismuth
abl
replac
bound
zinc
protein
figur
significantli
bind
bismuth
groe
alter
quaternari
structur
nativ
heptam
dimer
attribut
bismuth
bind
ntermin
zincsit
ctermin
metal
bind
domain
figur
taken
togeth
bismuth
drug
enter
h
pylori
may
interfer
nickel
homeostasi
bind
nickel
storag
protein
hpnhpnl
accessori
protein
hspa
respons
hydrogenas
ureas
synthesi
bismuth
drug
also
like
inhibit
proteas
ureas
activ
modul
cellular
oxid
stress
bismuth
drug
use
clinic
antimicrobi
activ
structur
character
bismuth
drug
shed
light
assembl
decomposit
drug
extens
studi
carri
explor
potenti
bismuth
drug
amazingli
bismuth
also
exhibit
vitro
activ
antileishmani
activ
antitumor
activ
antimoni
arsen
possess
current
bismuthcontain
compound
clinic
trial
treatment
either
cancer
viral
infect
nevertheless
recent
vitro
data
quit
encourag
extens
explor
may
need
futur
moreov
pretreat
bismuth
drug
reduc
sideeffect
anticanc
drug
cisplatin
may
also
offer
potenti
applic
bismuth
treatment
cancer
spite
extens
studi
knowledg
mechan
action
bismuth
drug
still
limit
accumul
data
indic
protein
enzym
like
target
bismuth
drug
interact
bismuth
drug
number
protein
character
individu
recent
integr
view
potenti
bismuth
drug
insid
h
pylori
given
aid
metallomicsmetalloproteom
approach
strategi
readili
extend
studi
mechan
metallodrug
well
evalu
uptak
storag
excurs
transit
metal
ion
